Imatinib: all 408 studies that test it
Page 4 of 5. Open to participants first (29), then studies with results posted, then the rest; newest registration first within each.
- Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic CarcinomaCompletedNCT00314873Phase 1
- Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00301093Phase 1
- Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib TherapyStatus unknownNCT00297570Phase 3
- Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal TumorsCompletedNCT00293124Phase 3
- Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)Status unknownNCT00290485Phase 2
- Imatinib Mesylate in Treating Patients With Recurrent or Refractory FibromatosisCompletedNCT00287846Phase 1/2
- Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in ChildrenCompletedNCT00287105Phase 2
- Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic CancerTerminatedNCT00281996Phase 1
- Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic LeukemiasStatus unknownNCT00276926Phase 2
- Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00268229Phase 1
- Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00258271Phase 1
- Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00253565Phase 1
- A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail GleevecCompletedNCT00250042Phase 2
- Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00248482Phase 2
- Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive LeukemiaCompletedNCT00244829Phase 1/2
- Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)CompletedNCT00237172Phase 2
- Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)CompletedNCT00237120Phase 3
- Phase II Gleevec Idiopathic Hypereosinophilic SyndromeTerminatedNCT00230334Phase 2
- Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung CancerCompletedNCT00222144Phase 2
- Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous PatientsTerminatedNCT00219765Phase 1/2
- Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 YearsCompletedNCT00219752Phase 2
- STI571 ProspectIve RandomIzed Trial: SPIRITCompletedNCT00219739Phase 3
- Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell TransplantationCompletedNCT00219726Phase 2
- Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian CancerCompletedNCT00216112Phase 2
- Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric AdenocarcinomaTerminatedNCT00209079Phase 2
- Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)Status unknownNCT00199186Phase 2
- Study of Xeloda and Gleevec in Patients With Advanced Solid TumorsCompletedNCT00183833Phase 1
- Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and NeckStatus unknownNCT00180921Phase 2
- Glivec Phase II Pediatric StudyTerminatedNCT00180830Phase 2
- Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT00171977Phase 4
- Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)TerminatedNCT00171938Phase 2
- Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
- Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)CompletedNCT00171899Phase 4
- A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic SyndromeTerminatedNCT00171860Phase 2
- Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.WithdrawnNCT00159016Phase 2
- Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLCCompletedNCT00156286Phase 2
- Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
- Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic LeukemiaCompletedNCT00154349Phase 2
- A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.CompletedNCT00154336Phase 2
- Efficacy and Safety of Imatinib in ChordomaCompletedNCT00150072Phase 2
- Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.Status unknownNCT00149136Phase 2
- AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One YearStatus unknownNCT00146913Phase 2
- A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)CompletedNCT00136409Phase 2
- Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)CompletedNCT00135005Phase 1
- Gleevec Idiopathic Pulmonary Fibrosis (IPF) StudyCompletedNCT00131274Phase 2/3
- Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)CompletedNCT00130195Phase 2
- Imatinib in Dermatofibrosarcoma Protuberans (DFSP)CompletedNCT00122473Phase 1/2
- Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)CompletedNCT00116935Phase 3
- BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib MesylateStatus unknownNCT00112775Phase 2
- Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal TumorCompletedNCT00112632Phase 2
- Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal TumorCompletedNCT00103168Phase 3
- Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00101088Phase 1
- Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib MesylateCompletedNCT00093639Phase 1/2
- Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By SurgeryTerminatedNCT00091078Phase 2
- PTK 787 and Gleevec in Patients With AML, AMM, and CML-BPCompletedNCT00088231Phase 1/2
- Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell FibroblastomaCompletedNCT00085475Phase 2
- Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008CompletedNCT00084825Phase 2
- Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma ProtuberansCompletedNCT00084630Phase 2
- Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing CancerCompletedNCT00084513Phase 1
- Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00081926Phase 4
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaCompletedNCT00081133Phase 1/2
- Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone MetastasesCompletedNCT00080678Phase 2
- Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00080665Phase 1
- Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous LeukemiaCompletedNCT00079313Phase 2
- S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell CancerCompletedNCT00068783Phase 2
- Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00066326Phase 1
- Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic CancerCompletedNCT00064285Phase 1
- Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell TumorCompletedNCT00062205Phase 2
- Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00055874Phase 3
- Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00054431Phase 2
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00053248Phase 1/2
- Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung CancerCompletedNCT00052949Phase 2
- Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00052494Phase 1
- Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00049192Phase 2
- Therapy of Early Chronic Phase CML With GleevecCompletedNCT00048672Phase 2
- Study of Lonafarnib and Gleevec in Chronic Myelogenous LeukemiaCompletedNCT00047502Phase 1
- Imatinib Mesylate in Treating Patients With Salivary Gland CancerCompletedNCT00045669Phase 2
- Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00045604Phase 1
- Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00045422Phase 2
- Imatinib Mesylate in Treating Patients With Metastatic Breast CancerCompletedNCT00045188Phase 2
- Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic SyndromeActive, not recruitingNCT00044304Phase 2
- Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian CancerTerminatedNCT00042952Phase 2
- Imatinib Mesylate in Treating Patients With Stage IV Colorectal CancerCompletedNCT00041340Phase 2
- Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By SurgeryCompletedNCT00041197Phase 3
- Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00041041Phase 2
- Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00040105Phase 1
- Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential TumorCompletedNCT00039585Phase 2
- Imatinib Mesylate in Treating Patients With MyelofibrosisCompletedNCT00039416Phase 2
- Imatinib Mesylate in Treating Patients With GliomasCompletedNCT00039364Phase 2
- Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate CancerCompletedNCT00038194Phase 1
- Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00036751Phase 2
- Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone SarcomaCompletedNCT00031915Phase 2
- Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of ChildhoodCompletedNCT00030667Phase 2
- Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00030394Phase 2
- Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid LeukemiaStatus unknownNCT00028847Phase 1/2
- Imatinib Mesylate in Treating Patients With Metastatic MelanomaCompletedNCT00027586Phase 2
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney FailureCompletedNCT00026169Phase 1
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
- Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During SurgeryCompletedNCT00025246Phase 2
- Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic LeukemiaCompletedNCT00022737Phase 3